NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Amneal Pharmaceuticals, Inc. AMRX
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.0B
▲ 8.0% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
2.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.0B
Revenue, FY2025 · full 10-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin13.1%
Net margin2.4%
Return on assets2.0%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+8.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+10.9%
+8.7%
Net income
+1.2%
EPS, diluted
−18.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.7B
total assets, end of FY2025
Total assetsUSD 3.7B
EquityUSD -70.8M
CashUSD 282.0M
Gross debtUSD 2.6B
Net debtUSD 2.3B
Current ratio2.17×
Net debt stands at -3235% of equity.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
3.0
2.8
2.4
2.2
2.1
2.0
1.6
1.7
1.0
1.0
Operating income $B
0.4
0.2
0.2
−0.1
0.2
0.1
−0.2
−0.0
0.2
0.3
EBITDA $B
0.5
0.3
0.3
−0.0
0.2
0.2
−0.2
0.0
0.3
0.3
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.1
0.4
−0.0
0.0
0.0
Net income $B
0.1
−0.1
−0.1
−0.3
0.0
0.1
−0.6
−0.0
0.0
0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
0
−0
−927
·
·
ROE %
·
·
−52.8
−77.4
4.0
25.3
−163.8
−7.8
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
33 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 3 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed